Asia-Pacific Cell & Gene Therapy report features an in-depth analysis of top Biopharma companies and CMOs focusing on Cell & Gene Therapy development and manufacturing in the APAC region. The report offers detailed insights from extensive primary and secondary research studies from geographies such as: China, South Korea, Japan, Taiwan, India, Singapore, Australia and SEA from pre-clinical, clinical (Phase I, II, III), to market approval/commercialization stages.

IMAPAC Pte Ltd performed an analysis of the APAC Cell & Gene therapy companies in the region to track their research & development and manufacturing capabilities. It presents current and future outlook of CGT market in APAC with exclusive interview transcripts and insights from the Cell & Gene therapy players. It offers in-depth details o on product pipelines, manufacturing facilities, service offerings, product manufacturing challenges and investment opportunities.

The report presents insights from conversations obtained from senior representatives of biopharma companies and CMOs on the following but not limited to:

• Cell & gene therapy market overview (size, growth, trends, drivers, etc)
• Detailed profiling of cell & gene therapy companies by geography
• Exclusive interview transcripts of CMOs and Biopharma companies
• Cell & gene therapy products in the pipeline
• Manufacturing facility highlights of CMOs and Biopharma
• Manufacturing services offerings of CMOs and Biopharma
• Manufacturing facility’s details (facility size, design, capacity, and many more)
• Products manufactured in the facility
• Bioprocessing tools, technologies, and equipment used in the facility
• Production batch size and process technologies employed
• Project details of CMOs and Biopharma
• GMP certifications and quality certifications details
• Team- distribution, facility investment and collaboration updates
• Future expansion updates and plans of CMOs and Biopharma

The first section of the report presents overview of Global Cell and Gene Therapy market rise for the period 2010-2030 with major focus on APAC market. The report findings reveal that APAC Cell & Gene Therapy Market is expected to reach USD 81 billion by the year 2025 at a CAGR of 40.34% during the forecast period of 2019-2025.

The second section focuses solely on CGT market growth and outlook within Asia-Pacific region. It is anticipated to have a market share of ~36% by 2030. This section also includes key drivers and trends of the market. It presents snippets of state of CGT market in each APAC region.

The third section includes the scope of the report with list of Cell and Gene Therapy companies established across APAC countries.

The fourth section covers expert poll analysis which has been conducted amongst Cell and Gene therapy companies. The analysis reveals findings across several question including the types of equipment that companies are looking to optimize and type of logging system currently used to collect and process clinical trial data.

The fifth section of the report includes interview excerpt of key Cell and Gene Therapy companies. These insights are unique and not available in the market. The information covered in this section is exclusive and it has been gathered through direct interview with top Biopharma and Contract manufacturers of CGT focus in APAC. An example of findings includes company’s plans to outsource their CGT product’s manufacturing activities to CMO in next 2-5 years and the name of equipment used in the CGT development along with their partnered solution providers. This type of insights is highly useful for developers and vendors of CGT products to keep track of partnership within the CGT space. The interview excerpts are available for companies including Medinet, Ever Supreme, Genome Frontier Therapeutics, UnicoCell, Kemwell Biopharma, Medipost and many other companies across APAC region.

The sixth section of the report covers detailed survey-based research & analysis of each Cell & Gene Therapy CMOs and biopharma companies in Greater China. It covers data on several topics for individual CGT companies including company snapshot, exclusive interview transcripts, manufacturing facility, services offerings, facility details such as facility size, design, capacity, etc, current products in manufacturing, R&D and cell manufacturing project details, bioprocessing tools, technologies, and equipment used in manufacturing, production batch size and process technologies employed, GMP & quality certifications details, team- distribution and facility investment updates, future expansion plans of CMOs and biopharma, financial insights into CMOs and biopharma, partnerships & collaborations for product development & manufacturing among other data.

The seventh section of the report provides exclusive insights from CGT companies in India. It covers data for each company on several topics for individual CGT companies including company snapshot, exclusive interview transcripts, manufacturing facility, services offerings, facility details such as facility size, design, capacity, etc, current products in manufacturing, R&D and cell manufacturing project details, bioprocessing tools, technologies, and equipment used in manufacturing, production batch size and process technologies employed, GMP & quality certifications details, team- distribution and facility investment updates, future expansion plans of CMOs and biopharma, financial insights into CMOs and biopharma, partnerships & collaborations for product development & manufacturing among other data.

The eight section includes in-depth researched data on CGT companies that are based in Korea. It covers data on several topics for individual CGT companies including company snapshot, exclusive interview transcripts, manufacturing facility, services offerings, facility details such as facility size, design, capacity, etc, current products in manufacturing, R&D and cell manufacturing project details, bioprocessing tools, technologies, and equipment used in manufacturing, production batch size and process technologies employed, GMP & quality certifications details, team- distribution and facility investment updates, future expansion plans of CMOs and biopharma, financial insights into CMOs and biopharma, partnerships & collaborations for product development & manufacturing among other data.

The ninth section presents detailed analysis of CGT companies operating in Japan. It covers data on several topics for individual CGT companies including company snapshot, exclusive interview transcripts, manufacturing facility, services offerings, facility details such as facility size, design, capacity, etc, current products in manufacturing, R&D and cell manufacturing project details, bioprocessing tools, technologies, and equipment used in manufacturing, production batch size and process technologies employed, GMP & quality certifications details, team- distribution and facility investment updates, future expansion plans of CMOs and biopharma, financial insights into CMOs and biopharma, partnerships & collaborations for product development & manufacturing among other data.

The tenth section of the report includes details insights for CGT companies in South-East Asian countries. It covers data on several topics for individual CGT companies including company snapshot, exclusive interview transcripts, manufacturing facility, services offerings, facility details such as facility size, design, capacity, etc, current products in manufacturing, R&D and cell manufacturing project details, bioprocessing tools, technologies, and equipment used in manufacturing, production batch size and process technologies employed, GMP & quality certifications details, team- distribution and facility investment updates, future expansion plans of CMOs and biopharma, financial insights into CMOs and biopharma, partnerships & collaborations for product development & manufacturing among other data.

The eleventh section of the report has survey-based information on CGT companies from Australia. It covers data on several topics for individual CGT companies including company snapshot, exclusive interview transcripts, manufacturing facility, services offerings, facility details such as facility size, design, capacity, etc, current products in manufacturing, R&D and cell manufacturing project details, bioprocessing tools, technologies, and equipment used in manufacturing, production batch size and process technologies employed, GMP & quality certifications details, team- distribution and facility investment updates, future expansion plans of CMOs and biopharma, financial insights into CMOs and biopharma, partnerships & collaborations for product development & manufacturing among other data.

The last section of the report has insights obtained from exclusive Interview with Rachit Jain, Global Cell and Gene Lead at Körber’s Business Area Pharma

The option to customize the report is available upon request to meet your data requirements which are not included in the report. The customized report is comparatively cost-effective and dependent on data requirements.

APAC Cell and Gene Therapy report features an extensive study of the Cell and Gene Therapy market for Asia-Pacific region. The report includes an in-depth study of current and future outlook of Cell and Gene Therapy market with drivers and trends observed in the industry. It features comprehensive analysis of Cell and Gene Therapy company profiles by geography, manufacturing facilities, R&D centres with detailed service offerings of Biopharma companies and CMOs focused in cell therapy development.

The report provides detailed overview on Cell and Gene Therapy companies including their interview transcripts, offerings, facility details such as size, design, production capacity. It tracks current products in pipeline and manufacturing, challenges faced by the company in addition to company’s current and completed projects. It highlights bioprocessing tools, equipment and technologies used by the biopharma and CMOs in the cell therapy products development, GMP certifications and regulations, future plans of CGT companies, partners and collaborators details and financial insights into CMOs and Biopharma with an objective to provide a view of competitive landscape and shed light on competitors clients.

Comprehensive country wise analysis of the APAC Cell & Gene Therapy companies covering trends in each Asian country and the technological advancement in this field.

Exclusive transcripts and insights through direct interview with key Cell and Gene Therapy Biopharma and CMOs obtained on basis of more than 20 survey questionnaire. The transcripts reveal unique insights into company’s future investment plans, strategies, partner’s and client’s details, upcoming products for development, manufacturing process highlights and other vital information.

IMAPAC Pte. Ltd. has released this report with an objective to support key industry stakeholders in co-development and other business-related partnerships, to plan future portfolio focus and to invest in research and technologies to fill the gaps identified. IMAPAC will continue tracking the developments in the industry and the implementation of its recommendations.

Asia-Pacific Cell & Gene Therapy Report with more than 265 page consists of 57 tables and 99 figures that are easy to comprehend. This report presents insights on the top CMOs and Biopharma organizations working on cell & gene therapy development and manufacturing in the APAC Market. It provides data analysis based on primary and secondary research targeting many aspects including products in development, manufacturing plant and facilities, technologies or bioprocessing equipment, collaborations, investments, company news and updates, future expansion plans, and much more.

This report is unique in that our charts and analyses figures are based on data collected directly from key representatives from the manufacturing team in focus. This report lets you understand your competitors better and assess the opportunities for investment in cell & gene therapy market across countries within Asia-Pacific region.

This report will assist you in critical decision making and help you to build informed strategies. The unique and detailed report will support your business plans and investments in Cell & Gene Therapy market.

Through our report, you are more likely to stay ahead of your competitors and expand your knowledge in Cell & Gene Therapy. This report may potentially help your research, analyses, and strategic decisions. IMAPAC’s Report is intended for anyone who demands comprehensive and in-depth analyses for key Cell & Gene Therapy Biopharma and CMOs.

The data in this report is researched and validated using primary and secondary research. The data is collected through multiple scientific and non-scientific sources including live discussions with experts through IMAPAC’s events and research reports, company websites, press releases, publicly available information, regulatory database and many more.

1. Global Cell and Gene Therapy Market Rise
2. CGT Market Outlook in APAC
3. Report Scope
4. Expert Poll Analysis
5. Interview Excerpts of CGT Companies
   • Medinet, Japan
   • Ever Supreme, Taiwan
   • Genome Frontier Therapeutics, Taiwan
   • Unicocell, Taiwan
   • Kemwell Biopharma, India
   • Medipost, South Korea
   • Maria Von Bio Technology, Taiwan
   • Zumutor, India
   • Gc Cell, South Korea
6. Facilities in Greater China
   • Carsgen Therapeutics
   • Cellular Biomedicine Group
   • Ever Supreme
   • Fullhope Biomedical
   • Hebei Senlangbio Technology
   • Genscript Probio
   • Shenzhen Yuanxing Gene Technology
   • Genome Frontier Therapeutics
   • Maria Von Stem Cell Med-Biotechnology
   • Obio Technology
   • Steminent Biotherapeutics
   • Taiwan Biotherapeutics
   • Unicocell
   • Wuxi Atu Co., Ltd
7. Facilities in India
   • Zumutor Biologics
   • Regenerative Medical Services Pvt. Ltd
   • Kemwell Biopharma
   • Stempeutics Research
8. Facilities in Korea
   • Corestem
   • Chabiotech
   • Eutilex
   • Green Cross Cell (Gc Cell)
   • Hapln Sciences
   • Kolon Life Sciences
   • Mdimune
   • Medipost
   • Pharmicell
   • S-Biomedics
   • Xcell Therapeutics
   • Tego Science
   • Anterogen
   • Sl Bigen
   • Scm Life Sciences
   • Curocell Co. Ltd
9. Facilities in Japan
   • Astellas
   • Brightpath Biotherapeutics
   • Healios K.K.
   • Hitachi
   • Medinet
   • Sumitomo Dainippon
   • Takara Bio
   • Thyas Co
10. Facilities in Southeast Asia
    • Cellvec
    • Esco Aster
    • Lion Tcr
    • Lonza Ag (Singapore)
    • Pt Kalbe (Stem Cell And Cancer Institute)
    • Singcell
    • Tcels
    • Tessa Therapeutics
11. Facilities in Australia
    • CELL THERAPIES PTY LTD
    • MESOBLAST

IMAPAC’s Exclusive Interview with Rachit Jain, Global Cell and Gene Lead at Körber’s Business Area Pharma

List of Tables

Table 1: Product pipeline of Ever-supreme Biotechnology

Table 2: Product Pipeline; Heibei senlang Bio

Table 3: Product pipeline: Genome Frontier Therapeutics

Table 4: Technologies used by Genome Frontier Therapeutics

Table 5: Facility highlights of Obio technology

Table 6: Product pipeline of Steminent Biotherapeutics

Table 7: Milestone Timeline; Taiwan Biotherapeutics

Table 8: Facility highlights of Unicocell

Table 9: Bioprocessing tools and equipment used and their solution providers; Unicocell

Table 10: Building 6 activities; WuXi ATU

Table 11: Building 7 activities: WuXi ATU

Table 12: Technique platforms used by WuXi ATU

Table 13: Product pipeline; Zumutor

Table 14: Facility highlights of Kemwell’s manufacturing plant in Bangalore

Table 15: Type and batch sizes of bioreactor used in Kemwell’s facility

Table 16: Liquid vial and lyophilised vial capacity; Kemwell Bipharma

Table 17: Equipment installed in Kemwell’s facility and their providers

Table 18: Current development status of PLX_PAD Cell Therapeutics

Table 19: Current Development Status of CordSTEM® Therapeutics

Table 20: Current Development Status of PlaSTEM

Table 21: Current Development Status of Fetal NPC and Adipocyte derived MSC Therapeutics

Table 22: Current Development Status of Immune Cell Based Therapeutics

Table 23: GC Cell company summary

Table 24: Facility Highlights GC Cell

Table 25: Facility highlights of Kolon Life Sciences’ B1 and B2 plants

Table 26: Facility Size of both plants in square ft: Kolon Lifesciences

Table 27: Equipment used in the bioprocessing value chain for B1 facility and their providers

Table 28: Equipment used in the bioprocessing value chain for B2 facility and their providers

Table 29: Facility highlights of Medipost’s manufacturing plant

Table 30: Checklist of their facility design and its flexibility

Table 31: Clinical trials for commercialisation

Table 32: National Projects carried out by Pharmicell

Table 33: Milestone timeline; Xcell Therapeutics

Table 34: Product pipeline; Xcell Therapeutics

Table 35: Manufacturing equipment and conditions used in the cGMP production facility

Table 36: Product development for xcell therapeutics

Table 37: Milestone timeline; Tego science

Table 38: Anterogen’s Products and Description

Table 39: Product pipeline; Tego Science

Table 40: Technologies used for SL Bigen’s products

Table 41: Product pipeline; SCM Life Sciences

Table 42: Facility highlights of Astella’s cell therapy manufacturing plants

Table 43: Milestones achieved by Healios

Table 44: Product Pipeline of Healios K.K

Table 45: Summary of new research facility; Healios

Table 46: Facility Highlights of Hitachi Chemical Advanced Therapetuics Yokohama facility

Table 47: Facility highlights of Sumitomo Dainippon’s plant

Table 48: Products under Sumitomo’s pipeline and their current development status, 2019

Table 49: iPS cell culture with automated cell culture equipment

Table 50: Facility highlights of Takara Bio

Table 51: Case Study 1:293- cell bank

Table 52: Case study 2: E.Coli- cell bank

Table 53: Contractors contracted by Takara Bio to build their CGCP

Table 54: Progress of Takara Bio’s main projects

Table 55: Services offered by Esco Aster

Table 56: Products, Indication and Stages of Development – Lion TCR

Table 57: Facility highlights of Lonza AG

List of Figures

Figure 1: Market Growth from 2017 to 2025

Figure 2: Roadmap for Stem Cell Development in Indonesia

Figure 3 Product Pipeline of Carsgen Therapeutics

Figure 4: CBMG’s pipeline for immuno- oncology products

Figure 5: CBMG’s pipeline for stem cell products

Figure 6: Key Milestones of Ever Supreme from 2016-2020

Figure 7: Development of Hebei Senlang

Figure 8: Hebei Senlang’s Pipelines in Hematology Malignancies

Figure 9: CAR-T research and manufacturing lab with 5000m2 space

Figure 10: Establishment of GenScript Probio Facilities

Figure 11 Services offered by GenScript ProBio in different stages of product development

Figure 12: The Cell Therapy Process in GenScript ProBio – GMP Plasmid and Virus Manufacture

Figure 13: The Gene Therapy process in GenScript ProBio – GMP Plasmid and Virus Manufacture

Figure 14: Services offered by Genscirpt

Figure 15: Projects completed by Genscript Bio

Figure 16: Quality compliant systems: Genscript Bio

Figure 17: Future expansion plans (2020-2023): GenScript ProBio

Figure 18: Comparison of Genome Frontiers’ technology versus other companies in disruptive CAR-T therapies

Figure 19: Product pipeline: Maria Von Stem Cell Bio

Figure 20: Services offered by Obio Technology

Figure 21: Milestone timeline; Obio Biotechnology

Figure 22: Snapshot of facility size of the manufacturing tumours

Figure 23: Quality control and assurance systems; Obio Biotechnology

Figure 24: Product pipeline for Taiwan Biotherapeutics

Figure 25: CLI & OA Knee Clinical Trial roadmap

Figure 26: Manufacturing area in the GMP facility

Figure 27: Core technology of cell therapy manufacturing; Unicocell

Figure 28: Global manufacturing sites of Wuxi AppTec

Figure 29: Manufacturing sites of WuXi ATU in China

Figure 30: Overview of services offered by WuXi ATU

Figure 31: Pipeline of Regrow Biosciences

Figure 32: Product Details of Cartigrow (Cartilage Cell Therapy) and Ossgrow (Bone Cell Therapy) of Regrow Biosciences

Figure 33: Action Mechanism of Regrow Biosciences’ platform

Figure 34: Regrow Biosciences Cell Therapy platform

Figure 35: Stempeutic’s product pipeline; 2020

Figure 36: Product pipeline of Corestem

Figure 37: NEURONATA-R by Corestem, as posted on MDFS

Figure 38: Technology Infrastructure for R&D and Commercialization of Cell-based Medicine; Corestem

Figure 39: Revenue in USD millions from 2016-2019

Figure 40: Millstone Timeline; Chabiotech

Figure 41: Statement of Financial Position

Figure 42: Income Statement

Figure 43: Milestone timeline; Eutilex

Figure 44: Facility locations of GC Cell, as of September 2020

Figure 45: Image of GC Cell Facility, as of Sep 2020

Figure 46: Product pipeline for GC Cell facility, as of September 2020

Figure 47: Product description of Immuncell-LC of for GC Cell, as of September 2020

Figure 48: Cell Therapy Manufacturing Process in GC Cell, as of September 2020

Figure 49: Mechanism and Technology of Immuncell-LC GC Cell – Cell Types

Figure 50: Mechanism and Technology of Immuncell-LC, as of September 2020

Figure 51: Immuncell-LC yield per annum of GC Cell, as of September 2020

Figure 52: Clinical Trials and Target Diseases for C.A.T Technology, as of September 2020s

Figure 53: Active patents and status, as of September 2020

Figure 54: Shareholders split-up of GC Cell, As of 2019

Figure 55: Sales and Operating Profit 2014 – 2020; as of Oct 2020

Figure 56: Commercialization plan of CG CAR-T product 2019-2021

Figure 57: Product Pipeline of HAPLN Science

Figure 58: Services offered by Kolon Life Sciences

Figure 59: A closer look into the Process Development services offered; KLS

Figure 60: Equipment used in the facility; Kolon Life Sciences

Figure 61: Equipment used in the Quality Control area; Kolon Life Sciences

Figure 62: Product pipeline of S.Biomedics

Figure 63: Tego Science balance sheet

Figure 64: Tego Science Income statement

Figure 65: SCM’s Large-volume culture technology

Figure 66: CuroCell CAR technology mechanism

Figure 67: Astellas manufacturing plant in Toyoma Tumour

Figure 68: Astellas manufacturing plant in Tsukuba

Figure 69: Revenue and Annual Financial Statements 2019-2020

Figure 70: Yokohama Plant; Hitachi Chemical Advanced Therapeutics Solutions, 2020

Figure 71: Hitachi: Counter-Flow Centrifugation System

Figure 72: Hitachi Equipment found in the development room in Hitachi

Figure 73: Medinet developing commercialised regenerative medical products/ investigational products

Figure 74: Medinet’s Shinagawa CPF building layout

Figure 75: Location of Sumitomo’s offices and plant in Japan

Figure 76: Cell Therapy Manufacturing plant in Osaka Prefecture, Sumitomo Dainippon

Figure 77: Closed system used by Sumitomo for cell therapy manufacturing

Figure 78: Automated cell- culturing equipment

Figure 79: Comparison between manual method and closed system

Figure 80: Sumitomo: The high-throughput cell sorter used in the manufacturing plant

Figure 81: Gigasort system, Cytonome/ST, LLC, Cell Sorter

Figure 82: Immunotherapy Utilizing the iPS Technology to Rejuvenate Exhausted T cells

Figure 83: Thyas iPSC technology with clinical advancements

Figure 84: Partnerships and Collaboration of Thyas Co. Ltd

Figure 85: Testing Thyas’ T-cell Therapy in Human in 2020

Figure 86: Future Perspective of Thyas’ growth

Figure 87: Key milestones of Cellvec from 2017-2019

Figure 88: Technologies adopted by Esco Aster

Figure 89: IPSpheres Microcarrier Reprogramming Platform

Figure 90: Cost savings with Singcell’s technology

Figure 91: Singcell’s automated bioreactor

Figure 92: Comparison of Autologous CAR-T Manufacturing Technologies

Figure 93: Organizations in close partnership with TCels

Figure 94: TCels’ Cell & Gene Therapy Division

Figure 95: Facility Size of TCels Bioproduction Center

Figure 96: Product Pipeline and Stages of Development

Figure 97: Control of apheresis collections through five modules; CPTL

Figure 98: Clinical trials extended to Australia

Figure 99: Product Candidates and stages of development

Single – User Access

This license grants the right of use of the purchased report to a single recipient only. You may access the material on your computer, as and when required, for your own personal use.

Multi – User Access

Upto 3 users: This license grants the right of use of the purchased report by upto 3 users of the same firm/enterprise.

Corporate Access

Unlimited user access (Within your organization): This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the number of users.